Abstract
In 1996, due to a residual risk of transfusion-transmitted virus, a circular of the French Health Authorities (DGS/DH n° 96-609) recommended proposing to recipients of cellular blood products a test for antibodies to human immunodeficiency virus (HIV) and for antibodies to hepatitis C virus, before and three months after transfusion. We have evaluated the application of this recommendation throughout the whole transfused population of a French Hospital over a three month period. In addition, this study allowed us to establish the vaccination status against hepatitis B virus (HBV) infection in this exposed population including transfusion and nosocomial risks. The results showed a failure in the application of the 1996 circular and confirmed the validity of the abrogation of this circular by a recent circular (11 January 2006) of the French health authorities. It also showed that only a minority of patients needing a vaccination against HBV were afforded such treatment during their hospitalization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
